Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $615.00 at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn raised the price target for Intuitive Surgical from $610.00 to $615.00, maintaining a "buy" rating, indicating a potential upside of 16.09%.
• Intuitive Surgical reported $2.40 earnings per share for the latest quarter, surpassing analysts' expectations of $1.99, with a year-over-year revenue increase of 22.9%.
• The stock currently holds a consensus rating of "Moderate Buy" with a target price averaging $604.50, as per data from MarketBeat.com.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) had its price target raised by Rothschild & Co Redburn from $610.00 to $615.00 in a research note issued to investors on Thursday,MarketScreener reports. The brokerage currently has a "buy" rating on the medical equipment provider's stock. Rothschild & Co Redburn's price objective would indicate a potential upside of 16.09% from the stock's current price.

Other equities research analysts also recently issued research reports about the company. Raymond James Financial set a $603.00 price target on Intuitive Surgical and gave the stock an "outperform" rating in a report on Wednesday. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Leerink Partners boosted their price objective on shares of Intuitive Surgical from $593.00 to $600.00 and gave the company an "outperform" rating in a report on Wednesday. Royal Bank Of Canada set a $625.00 target price on Intuitive Surgical and gave the company an "outperform" rating in a research report on Wednesday. Finally, Truist Financial set a $620.00 price objective on Intuitive Surgical and gave the company a "buy" rating in a report on Wednesday. Eighteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus target price of $604.50.

Intuitive Surgical Stock Up 0.5%

NASDAQ:ISRG opened at $529.77 on Thursday. The stock has a market capitalization of $189.91 billion, a price-to-earnings ratio of 70.12, a PEG ratio of 4.86 and a beta of 1.61. Intuitive Surgical has a 52 week low of $425.00 and a 52 week high of $616.00. The firm has a 50 day moving average of $455.28 and a 200 day moving average of $495.80.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.03% and a net margin of 28.58%.The business had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the firm posted $1.84 earnings per share. The business's quarterly revenue was up 22.9% on a year-over-year basis. As a group, analysts expect that Intuitive Surgical will post 6.43 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares of the company's stock, valued at approximately $173,845.44. This represents a 92.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the completion of the sale, the insider directly owned 19,827 shares in the company, valued at approximately $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,224 shares of company stock worth $21,716,492 in the last 90 days. Corporate insiders own 0.70% of the company's stock.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently modified their holdings of the business. Chilton Capital Management LLC increased its position in Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the last quarter. Tobam increased its stake in Intuitive Surgical by 666.7% during the second quarter. Tobam now owns 46 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 40 shares during the period. Elite Financial Inc. acquired a new stake in shares of Intuitive Surgical during the first quarter worth about $26,000. Kilter Group LLC purchased a new position in shares of Intuitive Surgical in the second quarter valued at approximately $27,000. Finally, LFA Lugano Financial Advisors SA acquired a new position in shares of Intuitive Surgical in the first quarter valued at approximately $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.